Kronos Bio CDK9 inhibitor selective structure drug hunter molecules of the year KB-0742

selective CDK9 inhibitor

oral Ph. I candidate for MYC-amp tumors

from microarray binding assay with lysate


Kronos Bio, Cambridge, MA

The Kronos CDK9 inhibitor, KB-0742, is an ultraselective inhibitor of cyclin-dependent kinase CDK9. The CDK family of kinases have been pursued as cancer drug targets for decades, but family…

     this content is exclusive to
    Premium members

    Upgrade to a Premium Drug Hunter membership to unlock the full content and start reading now.